Single inhaler strategy in stepwise therapy of bronchial asthma: GINA 2014 update
https://doi.org/10.18093/0869-0189-2014-0-6-83-93
Abstract
Major advances of GINA (Global Initiative for Asthma) 2014 pertinent to definition, phenotypes and stepwise approach for adjusting treatment of asthma have been viewed in the article. The attention was focused on combinations of low-dose inhaled steroid (ICS) / formoterol (FOR) both as maintenance and reliever therapy (single inhaler strategy) or ICS / long-acting β2-agonist (LABA) as maintenance therapy plus short-acting β2-agonist (SABA) as-needed that are preferred options for treatment steps 3–4 in adults and adolescents. GINA experts emphasize that the single inhaler strategy is the treatment of choice for asthma patients with steps 3–4 experienced ≥ 1 exacerbation during the previous year. Administration of budesonide (BUD) / FOR as a single inhaler is recommended for patients > 18 years old with insufficient asthma control and frequent need in SABA. BUD / FOR as a single maintenance and reliever inhaler could reduce frequency of severe asthma exacerbations requiring hospitalizations and use of systemic steroids, improve asthma symptoms and lung function when compared to other treatment regimens. Preventive effects of BUD / FOR combination are provided by anti-inflammatory effect which is timely amplified by additional inhalations of the drug.
About the Author
N. M. Nenasheva
State Institution of Аdditional Еducation "Russian Medical Postgraduate Academy", Healthcare Ministry of Russia, 2 / 1, Barrikadnaya ul., Moscow, 123995, Russia Summary
Russian Federation
Russian Federation
MD, Professor of Chair of Clinical Allergology, State Budget Educational Institution of Аdditional Еducation "Russian Medical Postgraduate Academy", Healthcare Ministry of Russia; tel.: (499) 196-17-86
References
1. GINA 2014. www.ginasthma.org
2. Чучалин А.Г., Айсанов З.Р., Белевский А.С. и др. Федеральные клинические рекомендации по диагностике и лечению бронхиальной астмы. Пульмонология. 2014; 2: 11–32. / Chuchalin A.G., Aysanov Z.R., Belevskiy A.S. et al. Federal guidelines on diagnosis and treatment of bronchial asthma. Pul'monologiya. 2014; 2: 11–32 (in Russian).
3. Martin R.J., Szefler S.J., King T.S. et al. National Heart, Lung, and Blood Institutes Asthma Clinical Research Center. The Predicting Response to Inhaled Corticosteroid Efficacy (PRICE) trial. J. Allergy Clin. Immunol. 2007; 119 (1): 73–80.
4. Berry M., Morgan A., Shaw D.E. et al. Pathological features and inhaled corticosteroid response of eosinophilic and noneosinophilic asthma. Thorax. 2007; 62: 1043–1049.
5. Thomson N.C., Chaudhuri R., Livingston E. Asthma and cigarette smoking. Eur. Respir. J. 2004; 24: 822–833.
6. Holguin F., Bleecker E.R., Busse W.W. et al. Obesity and asthma: an association modified by age of asthma onset. J. Allergy Clin. Immunol. 2011; 127: 1486–1493.
7. Berthon B., Macdonald-Wicks L., Gibson P., Wood L. Investigation of the association between dietary intake, disease severity and airway inflammation in asthma. Respirology. 2013; 18: 447–454.
8. Foschino Barbaro M.P., Costa V.R., Resta O. et al. Menopausal asthma: a new biological phenotype? Allergy. 2010; 65: 1306–1312.
9. Barnes P.J. Scientific rationale for inhaled combination therapy with long-acting beta2-agonists and corticosteroids. Eur. Respir. J. 2002; 19 (1): 182–191.
10. Ducharme F.M., Ni Chroinin M., Greenstone I., Lasserson T.J. Addition of long-acting beta2-agonists to inhaled steroids versus higher dose inhaled steroids in adults and children with persistent asthma. Cochrane Database Syst. Rev. 2010; Apr. 14; (4): CD005533. DOI: 10.1002/14651858. CD005533.pub2.
11. Bateman E.D., Boushey H.A., Bousquet J. et al. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study. Am. J. Respir. Crit. Care Med. 2004; 170: 836–844.
12. Инструкция по медицинскому применению препарата Симбикорт Турбухалер 80 / 4,5 мкг и 160 / 4,5 мкг. Регистрационное удостоверение П No 13167/01. (Изменение No 2 от 21.02.13). / Prescription Drug Leaflet for Symbicort Turbuhaler 80 / 4.5 μg and 160 / 4.5 μg. Registration number П No 13167/01 (change N2, 21.02.13) (in Russian).
13. Moore W.C., Bleecker E.R., Curran-Everett D. et al. Characterization of the severe asthma phenotype by the National Heart, Lung, and Blood Institute's Severe Asthma Research Program. J. Allergy Clin. Immunol. 2007; 119: 405–413.
14. Bai T.R., Vonk J.M., Postma D.S., Boezen H.M. Severe exacerbations predict excess lung function decline in asthma. Eur. Respir. J. 2007; 30: 452–456.
15. Wu A.C., Tantisira K., Li L. et al. Predictors of symptoms are different from predictors of severe exacerbations from asthma in children. Chest. 2011; 140: 100–107.
16. O'Byrne P.M., Bisgaard H., Godard P.P. et al. Budesonide / formoterol combination therapy as both maintenance and reliever medication in asthma. Am. J. Respir. Crit. Care Med. 2005; 171: 129–136.
17. Rabe K.F., Atienza T., Magyar P. et al. Effect of budesonide in combination with formoterol for reliever therapy in asthma exacerbations: a randomised controlled, double-blind study. Lancet. 2006; 368: 744–753.
18. Bousquet J., Boulet L.P., Peters M.J. et al. Budesonide / formoterol for maintenance and relief in uncontrolled asthma vs. high-dose salmeterol / fluticasone. Respir. Med. 2007; 101: 2437–2446.
19. Bateman E.D., Harrison T.W., Quirce S. et al. Overall asthma control achieved with budesonide / formoterol maintenance and reliever therapy for patients on different treatment steps. Respir. Res. 2011, 12: 38.
20. Prazma C.M., Kral K.M., Gul N. et al. Controller medications and their effects on asthma exacerbations temporally associated with upper respiratory infections. Respir. Med. 2010; 104: 780–787.
21. Reddel H., Jenkins C., Quirce S. et al. Effect of different asthma treatments on risk of cold-related exacerbations. Eur. Respir. J. 2011; 38: 584–593.
22. Cates C.J., Karner C. Combination formoterol and budesonide as maintenance and reliever therapy versus current best practice (including inhaled steroid maintenance), for chronic asthma in adults and children. Cochrane Database Syst. Rev. 2013. DOI: 10.1002/14651858.CD007313.pub3.
23. Kew K.M., Karner C., Mindus S.M., Ferrara G. Combination formoterol and budesonide as maintenance and reliever therapy versus combination inhaler maintenance for chronic asthma in adults and children. Cochrane Database Syst. Rev. 2013. Dec 16; 12:CD009019.
24. Barnes P.J. Scientific rationale for using a single inhaler for asthma control. Eur. Respir. J. 2007; 29 (3): 587–595.
25. Gibson P.G., Saltos N., Fakes K. Acute anti-inflammatory effects of inhaled budesonide in asthma: a randomized controlled trial. Am. J. Respir. Crit. Care Med. 2001; 163: 32–36.
26. Kelly M., O'Connor T., Leigh R. et al. Effects of budesonide and formoterol on allergen-induced airway responses, inflammation, and airway remodeling in asthma. J. Allergy Clin. Immunol. 2010; 125: 349–356.
27. Ankerst J. Combination inhalers containing inhaled corticosteroids and long-acting beta2-agonists: improved clinical efficacy and dosing options in patients with asthma. J. Asthma. 2005; 42 (9): 715–724.
28. Toogood J.H., Baskerville J.C., Jennings B. et al. Influence of dosing frequency and schedule on the response of chronic asthmatics to the aerosol steroid, budesonide. J. Allergy Clin. Immunol. 1982; 70 (4): 288–298.
29. Архипов В.В., Григорьева Е.В., Гавришина Е.В. Контроль над бронхиальной астмой в России: результаты многоцентрового наблюдательного исследования НИКА. Пульмонология. 2011; 6: 87–93. / Arkhipov V.V., Grigor'eva E.V., Gavrishina E.V. Asthma control in Russia: results of the multicenter observational study NIKA. Pul'monologiya. 2011; 6: 87–93 (in Russian).
30. Nanshan Zhong, Jiangtao Lin, Parthiv Mehta et al. Reallife effectiveness of budesonide / formoterol maintenance and reliever therapy in Asthma Patients Across Asia. BMC Pulm. Med. 2013; 13 (22). DOI: 10.1186/1471-2466-13-22.
31. Søes-Petersen U., Kava T., Dahle R. et al. Budesonide / formoterol maintenance and reliever therapy versus conventional best standard treatment in asthma in an attempted 'real life' setting. Clin. Respir. J. 2011; 5 (3): 173–182.
32. van der Palen J., Klein J.J., van Herwaarden C.L.A.et al. Multiple inhalers confuse asthma patients. Eur. Respir. J. 1999; 14 (5): 1034–1037.
33. Sears M., Radner F. Safety of budesonide / formoterol maintenance and reliever therapy in asthma trials. Respir. Med. 2009; 103: 1960–1968.
34. Scicchitano R., Aalbers R., Ukena D. et al. Efficacy and safety of budesonide / formoterol single inhaler therapy versus a higher dose of budesonide in moderate to severe asthma. Curr. Med. Res. Opin. 2004; 20: 1403–1418.
35. Rabe K.F., Pizzichini E., St?llberg B. et al. Budesonide / formoterol in a single inhaler for maintenance and relief in mild-to-moderate asthma: A randomised, double-blind trial. Chest. 2006; 129: 246–256.
Review
For citations:
Nenasheva N.M. Single inhaler strategy in stepwise therapy of bronchial asthma: GINA 2014 update. PULMONOLOGIYA. 2014;(6):83-93. (In Russ.) https://doi.org/10.18093/0869-0189-2014-0-6-83-93
Views:
1600
Email this article 